Purinergic Signalling

Top Research Topics at Purinergic Signalling?

Purinergic Signalling explores disciplines such as Receptor, Cell biology, Purinergic receptor, Adenosine and Purinergic signalling. Topics in Receptor were tackled in line with various other fields like Endocrinology and Pharmacology. Pharmacology research presented in it encompasses a variety of subjects, including Agonist and Antagonist.

Extracellular and Signal transduction are all subfields of Cell biology research that were featured in it. Extracellular research discussed connects with the study of Intracellular. The studies on Purinergic receptor discussed can also contribute to research in the domains of Inflammation, Microglia, Immunology and Stimulation.

Topics in Adenosine explored in the journal were investigated in conjunction with research in Adenosine A3 receptor, Adenosine A1 receptor, Adenosine receptor, Adenosine A2B receptor and Adenosine A2A receptor. It addresses concerns in the field of Purinergic signalling by exploring it in line with topics in Neuroscience which intersect with Glutamate receptor subjects. In the Biochemistry research discussed, G protein-coupled receptor and Nucleotide are all tackled.

• Receptor (37.40%)
• Cell biology (29.59%)
• Purinergic receptor (26.62%)

What are the most cited papers published in the journal?

• The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance (724 citations)
• Cellular function and molecular structure of ecto-nucleotidases (634 citations)
• Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade (434 citations)

Research areas of the most cited articles at Purinergic Signalling:

The journal papers cover a variety of subjects, including Receptor, Purinergic receptor, Cell biology, Purinergic signalling and Biochemistry. While work presented in the published papers provide substantial information on Receptor, it also covers topics in Inflammation, Neuroscience and Pharmacology. The most cited publications with studies in Purinergic signalling featured incorporate elements of Endocrinology, Adenosine and Adenosine triphosphate.

What topics the last edition of the journal is best known for?

• Gene
• Enzyme
• Internal medicine

The previous edition focused in particular on these issues:

The journal mainly deals with areas of study such as Purinergic signalling, Receptor, Human physiology, Pharmacology toxicology and Purinergic receptor. The Purinergic signalling works featured in it incorporate elements from Adenosine, Neuroscience, Paracrine signalling and Cell biology. Adenosine research featured in it incorporates concerns from various other topics such as Purine and Nucleoside.

The featured works in Pannexin and Extracellular, which all belong in the domain if Cell biology, also overlaps with concepts under Context (language use). Adenosine receptor and G protein-coupled receptor studies are all carried out as a component of the study in Receptor presented. In addition to Purinergic receptor research, Purinergic Signalling aims to explore topics under Cancer research, Neuropathic pain, Pharmacology, Inflammation and Immune system.

The most cited articles from the last journal are:

• Ectonucleoside triphosphate diphosphohydrolases and ecto-5'-nucleotidase in purinergic signaling: how the field developed and where we are now. (8 citations)
• P2X7 is a cytotoxic receptor….maybe not: implications for cancer (8 citations)
• Nociceptive signaling of P2X receptors in chronic pain states. (5 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Purinergic Signalling (based on the number of publications) are:

• Geoffrey Burnstock (60 papers) absent at the last edition,
• Christa E. Müller (28 papers) published 1 paper at the last edition, 1 less than at the previous edition,
• Simon C. Robson (27 papers) published 1 paper at the last edition,
• Kenneth A. Jacobson (22 papers) absent at the last edition,
• Jean Sévigny (21 papers) published 3 papers at the last edition, 2 more than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Purinergic Signalling (based on the number of publications) are:

• University of Melbourne (36 papers) absent at the last edition,
• Leipzig University (29 papers) published 5 papers at the last edition, 4 more than at the previous edition,
• University of Bonn (28 papers) published 2 papers at the last edition the same number as at the previous edition,
• National Institutes of Health (27 papers) published 2 papers at the last edition, 2 less than at the previous edition,
• Universidade Federal do Rio Grande do Sul (23 papers) published 3 papers at the last edition the same number as at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 2.78% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 34.29% were posted by at least one author from the top 10 institutions publishing in the journal. Another 12.86% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 22.86% of all publications and 30.00% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Pathway to Becoming a Pharmacist in Biomedical Research

An important consideration for aspiring researchers in the Pharmacology field is understanding the career trajectory and requirements. Specifically, if one opts to delve into pharmacological research, knowing how to become a licensed pharmacist is pivotal. For example, in North Dakota, there are several steps that a prospect needs to take. Becoming a pharmacist requires an extensive amount of schooling and licensure examinations, specifically in North Dakota. Plunging into the nitty-gritty, the first step is to earn a Doctor of Pharmacy degree, typically a four-year program. This is followed by the completion of a residency or internship program, which lasts between one to two years. Following this, students must pass two exams: the North American Pharmacist Licensure Exam (NAPLEX) and the Multistate Pharmacy Jurisprudence Exam (MPJE). Given the intricacies of the profession, it's significant to highlight that these are merely broad steps to becoming a pharmacist. The possession of particular skill sets like analytical thinking, a detail-oriented mindset, and robust communication skills are also deemed crucial in the profession. For a more comprehensive understanding of the pathway to becoming a licensed pharmacist in North Dakota, feel free to check out our detailed guide how long does it take to become a pharmacist in north dakota. This will arm aspiring pharmacists with more personalized advice to conquer their dream profession.